Koselugo, also known as selumetinib, is a medication that has been approved by the FDA for the treatment of neurofibromatosis type 1 (NF1) in pediatric patients. NF1 is a genetic disorder that causes tumors to grow on nerves throughout the body, leading to a variety of symptoms and complications.
Koselugo works by targeting a specific protein in the body that is involved in the growth of these tumors. By inhibiting this protein, the medication can help to slow down or even shrink the tumors, improving symptoms and quality of life for patients with NF1.
It is important to note that Koselugo is specifically indicated for pediatric patients with NF1 who have symptomatic, inoperable plexiform neurofibromas. It is typically taken orally twice a day, with or without food, as directed by a healthcare provider.
As with any medication, there are potential side effects to be aware of when taking Koselugo. These can include gastrointestinal issues, skin rashes, and changes in vision. It is important to discuss any concerns or potential side effects with your healthcare provider.
Overall, Koselugo represents a significant advancement in the treatment of NF1, offering hope for patients and their families. If you or your child has been diagnosed with NF1 and are considering treatment options, be sure to speak with your healthcare provider about whether Koselugo may be a suitable option for you.
EN 
ES 
FR 
PT 
ZH